All In Biotech

Drug Trial Radar · NCT05404529

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

A Phase 1 Open-label Trial to Evaluate the Pharmacokinetics and Safety Following Single Dose of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: May 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Apr 29, 2022

Primary completion

Jan 24, 2023

Study completion Jan 24, 2023

Sponsor

Lead sponsor
Cerevel Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Jun 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • TavapadonDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7
  2. Area Under the Plasma Concentration-time Curve from Time Zero to t (AUC0-t) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7
  3. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of TavapadonTime frame: pre-dose and at multiple timepoints post-dose up to Day 7

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Miami, Florida

    Miami, Florida

  • Orlando, Florida

    Orlando, Florida

  • San Antonio, Texas

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.